| scholarly article | Q13442814 |
| P50 | author | Xuechuan Hong | Q42863996 |
| P2093 | author name string | Hui Zhou | |
| Michael X Zhu | |||
| Hongbo Wang | |||
| Yuling Xiao | |||
| Guangyao Lv | |||
| Qingjun Zhou | |||
| Chunhong Yan | |||
| Jingwen Zhang | |||
| Huai-Rong Luo | |||
| Jinbin Tian | |||
| Yingmin Zhu | |||
| Chunrong Qu | |||
| Fuchun Xu | |||
| Xiaodong Zeng | |||
| Jiacheng Lin | |||
| Yungang Lu | |||
| Zixing Deng | |||
| Mingmin Ding | |||
| P2860 | cites work | The discovery of potent blockers of the canonical transient receptor channels, TRPC3 and TRPC6, based on an anilino-thiazole pharmacophore | Q44355684 |
| Blockade of TRPC6 channels induced G2/M phase arrest and suppressed growth in human gastric cancer cells. | Q45926994 | ||
| Discovery of the Irreversible Covalent FGFR Inhibitor 8-(3-(4-Acryloylpiperazin-1-yl)propyl)-6-(2,6-dichloro-3,5-dimethoxyphenyl)-2-(methylamino)pyrido[2,3-d]pyrimidin-7(8H)-one (PRN1371) for the Treatment of Solid Tumors. | Q45991914 | ||
| Critical role of TRPC6 channels in VEGF-mediated angiogenesis | Q47942617 | ||
| Synthesis and Biological Evaluation of N-Heterocyclic Indolyl Glyoxylamides as Orally Active Anticancer Agents | Q53933668 | ||
| Gastric cancer | Q89391950 | ||
| Design and synthesis of novel human epidermal growth factor receptor 2 (HER2)/epidermal growth factor receptor (EGFR) dual inhibitors bearing a pyrrolo[3,2-d]pyrimidine scaffold | Q27675102 | ||
| Global cancer statistics, 2012 | Q27860501 | ||
| Molecular targeted therapy for the treatment of gastric cancer | Q28072433 | ||
| TRPC6 is a glomerular slit diaphragm-associated channel required for normal renal function | Q28594959 | ||
| TRPC3 and TRPC6 are essential for angiotensin II-induced cardiac hypertrophy | Q30478281 | ||
| Clinical impact of tumour biology in the management of gastroesophageal cancer | Q33922534 | ||
| Identification of ML204, a novel potent antagonist that selectively modulates native TRPC4/C5 ion channels | Q33973423 | ||
| Novel pharmacological TRPC inhibitors block hypoxia-induced vasoconstriction | Q34142319 | ||
| A mutation in the TRPC6 cation channel causes familial focal segmental glomerulosclerosis | Q34416768 | ||
| Preparation, pharmacokinetics, biodistribution, antitumor efficacy and safety of Lx2-32c-containing liposome | Q34702599 | ||
| Discovery and pharmacological characterization of a novel potent inhibitor of diacylglycerol-sensitive TRPC cation channels | Q35595863 | ||
| Identification and optimization of 2-aminobenzimidazole derivatives as novel inhibitors of TRPC4 and TRPC5 channels | Q35865421 | ||
| Discovery and Pharmacokinetic and Pharmacological Properties of the Potent and Selective MET Kinase Inhibitor 1-{6-[6-(4-Fluorophenyl)-[1,2,4]triazolo[4,3-b]pyridazin-3-ylsulfanyl]benzothiazol-2-yl}-3-(2-morpholin-4-ylethyl)urea (SAR125844). | Q36064085 | ||
| TRPC6 specifically interacts with APP to inhibit its cleavage by γ-secretase and reduce Aβ production. | Q36417516 | ||
| Deletion of TRPC4 and TRPC6 in mice impairs smooth muscle contraction and intestinal motility in vivo. | Q37376306 | ||
| Triazole-dithiocarbamate based selective lysine specific demethylase 1 (LSD1) inactivators inhibit gastric cancer cell growth, invasion, and migration. | Q37436085 | ||
| Enhanced expression of transient receptor potential channels in idiopathic pulmonary arterial hypertension | Q37533998 | ||
| Combined TRPC3 and TRPC6 blockade by selective small-molecule or genetic deletion inhibits pathological cardiac hypertrophy | Q37543708 | ||
| Targeting TRPC6 channels in oesophageal carcinoma growth. | Q37710561 | ||
| Vitamin D3 Prevents Calcium-Induced Progression of Early-Stage Prostate Tumors by Counteracting TRPC6 and Calcium Sensing Receptor Upregulation | Q38729304 | ||
| Natural product modulators of transient receptor potential (TRP) channels as potential anti-cancer agents | Q38738962 | ||
| Design, synthesis, and structure-activity relationship of novel LSD1 inhibitors based on pyrimidine-thiourea hybrids as potent, orally active antitumor agents | Q38917642 | ||
| Novel pyrazole compounds for pharmacological discrimination between receptor-operated and store-operated Ca(2+) entry pathways | Q39302766 | ||
| Transient receptor potential channel C3 contributes to the progression of human ovarian cancer | Q39893829 | ||
| Pyrazolopyrimidines as Potent Stimulators for Transient Receptor Potential Canonical 3/6/7 Channels | Q40250028 | ||
| Identification and Validation of Larixyl Acetate as a Potent TRPC6 Inhibitor. | Q40325030 | ||
| TRPC6 G757D Loss-of-Function Mutation Associates with FSGS. | Q40974180 | ||
| Long-term spironolactone treatment reduces coronary TRPC expression, vasoconstriction, and atherosclerosis in metabolic syndrome pigs. | Q42339342 | ||
| Chronic hypoxia-induced upregulation of store-operated and receptor-operated Ca2+ channels in pulmonary arterial smooth muscle cells: a novel mechanism of hypoxic pulmonary hypertension | Q42464729 | ||
| P304 | page(s) | 47-55 | |
| P577 | publication date | 2018-05-31 | |
| P1433 | published in | Cancer Letters | Q326372 |
| P1476 | title | Pyrazolo[1,5-a]pyrimidine TRPC6 antagonists for the treatment of gastric cancer | |
| P478 | volume | 432 |
| Q93165211 | Analysis of Mrgprb2 Receptor-Evoked Ca 2+ Signaling in Bone Marrow Derived (BMMC) and Peritoneal (PMC) Mast Cells of TRPC-Deficient Mice |
| Q64901873 | Novel near-infrared II aggregation-induced emission dots for in vivo bioimaging. |
| Q89823407 | PCC0208017, a novel small-molecule inhibitor of MARK3/MARK4, suppresses glioma progression in vitro and in vivo |
| Q58720903 | Prediction of key genes and pathways involved in trastuzumab-resistant gastric cancer |
| Q90395894 | TRP Channels in Digestive Tract Cancers |
| Q89468002 | TRPC channels: Structure, function, regulation and recent advances in small molecular probes |
Search more.